Brainstorm Cell Therapeutics (BCLI) Tops Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq eyes lower open after midterms-fueled surge as chip, data center stocks fall
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
- Unity Software stock soars 22% on strong Q3 beat, robust guidance
Tweet
Share
E-mailGet Alerts BCLI Hot Sheet
Join SI Premium – FREE
Note: EPS may not be comparable
Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q4 EPS of ($0.26), $0.01 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $0 , versus $0 reported last year.
For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Loar Holdings Inc. (LOAR) Reports Q3 EPS of $0.39 ; Offers Guidance
- DXP Enterprises (DXPE) Misses Q3 EPS by 1c
- Vericel (VCEL) Tops Q3 EPS by 21c; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
